Avutometinib
Avutometinib is an inhibitor of Ras-Raf-MEK-ERK signaling being developed as a potential treatment for cancer.
It was discovered by Chugai Pharmaceutical Co. through derivatization of a hit compound identified by high-throughput screening. It was licensed by Verastem Oncology in 2020 for clinical trials.
The co-packaged medication avutometinib/defactinib was approved for medical use in the United States in May 2025.